
Opinion|Videos|December 23, 2024
Patient Education: Preparing Patients for Bispecific Treatment in R/R MM
Advertisement
Episodes in this series

Video content above is prompted by the following:
1. How do you approach patient education regarding potential adverse events associated with talquetamab and other bispecific therapies?
Advertisement
Related to this article

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
4
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
5

